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Born at 27 weeks of gestationwith classical PKU: challengesof dietetic management in avery preterm infant
Diana Ballhausen,1 Delphine Egli,2Myriam Bickle-Graz,3 Nicoletta Bianchi,2Luisa Bonafé11Division of Molecular Pediatrics, 2ClinicalNutrition Unit, 3Developmental Unit,Centre Hospitalier Universitaire Vaudois,Lausanne, Switzerland
Abstract 
Few cases of premature infants with classi-
cal phenylketonuria (PKU) have been report-
ed. Treatment of these patients is challenging
due to the lack of a phenylalanine (Phe)-free
amino acid (AA) solution for parenteral nutri-
tion. A boy born at 27 weeks of gestation with
a weight of 1000 g was diagnosed with classi-
cal PKU on day 7 because of highly elevated
Phe level at newborn screening (2800 μmol/L).
Phe intake was suspended for 5 days and dur-
ing this time intravenous glucose and lipids as
well as small amounts of Phe-free formula
through nasogastric tube were given. Because
of insufficient weight gain attributable to defi-
ciency of essential AA, a Phe-reduced, BCAA-
enriched parenteral nutrition was added to sat-
isfy AA requirements without overloading in
Phe. Under this regimen, the boy started to
gain weight, Phe plasma levels progressively
reduced and normalized on day 19. At the age
of 40 months, the patient shows normal growth
parameters (height 25th percentile, weight 25-
50th percentile, head circumference 50th per-
centile) with a normal result for formally test-
ed psychomotor development (WPPSI-III). The
good outcome of the patient in spite of over 2
weeks of extremely high Phe concentrations
suggests that the premature brain may still
have enough plasticity to recover. Lacking a
Phe-free intravenous AA solution, successful
management of premature infants with PKU
depends on the child’s tolerance of enteral
nutrition. Although the coincidence of PKU
and prematurity is rare, there is strong need
for the development of an appropriate Phe-free
amino acid solution for parenteral nutrition
especially in case of gastro-intestinal compli-
cations of prematurity.
Introduction
Phenylketonuria (PKU; OMIM #261600) is an
autosomal recessive inherited defect of pheny-
lalanine hydroxylase (PAH, OMIM *612349, EC
1.14.16.1). PAH hydroxylates phenylalanine
(Phe) to tyrosine (Tyr) in the presence of
molecular oxygen and catalytic amounts of
tetrahydrobiopterin (BH4), its essential cofac-
tor. The PAH gene is located on chromosome
12q24.1 and a high number of allelic variants
are known (www.biopku.org). PKU has an over-
all incidence in Europe and the USA of approxi-
mately 1:10,000-20,000 live births.1 If left
untreated, PKU results in elevated blood Phe
concentrations, low-to-normal blood Tyr concen-
trations and severe mental retardation with an
intelligence quotient (IQ) between 30 and 50.2
Reduced cerebral monoaminergic neurotrans-
mitters and reduced protein synthesis, caused
by impaired brain uptake of non-Phe large neu-
tral amino acids in the presence of elevated
plasma Phe concentrations seem to be the main
pathophysiologic mechanism in PKU.3 The aim
of the treatment is to reduce the plasma Phe
concentration sufficiently to prevent neurologi-
cal impairment. Plasma Phe concentration
results from residual PAH activity, nutritional
Phe intake and growth rate. Depending on the
residual enzyme activity a more or less strict
reduction of dietary Phe intake is necessary to
achieve the desired plasma Phe concentration.
Complementation with a Phe-free amino acid
mixture is necessary in the majority of patients
to prevent protein deprivation and assure nor-
mal growth. Furthermore, there is a whole
range of low-protein food available to replace
protein-rich dietary components.2 In classical
PKU this treatment is very restrictive and may
be associated with a risk of nutritional deficien-
cies. During intercurrent illness a high-energy
intake is necessary to counteract catabolism of
body protein leading to higher plasma Phe lev-
els. Sick children are often unable to take their
prescribed diet and need calory administration
via naso-gastric tube or intravenously. The
treatment of premature PKU patients is very dif-
ficult as there are neither data about daily Phe
requirements nor specialized products for this
age group. Promotion of anabolism (energy
requirement for growing premature infants:
110-130 kcal/kg/d) seems to be the best rational
to stabilize plasma Phe levels. National guide-
lines of several European countries for the man-
agement of PKU recommend that treatment
should start as early as possible after birth and
should be monitored by Phe concentrations in
blood and clinical parameters.4-6 It is known that
the developing brain is most sensitive to Phe
toxicity, In 2000 Burgard showed that the IQ
decreased by 0.5 standard deviation (approxi-
mately 7 points) for each 300 μmol/L rise in
blood Phe level. IQ scores appeared to stabilize
after the age of 10 years, even when Phe levels
exceeded 1200 μmol/L, suggesting that diet
could be somewhat relaxed in adolescence.7
Indeed, until recently, diet was stopped in many
countries after the age of 12 years. In a longitu-
dinal collaborative study Koch et al reported that
early-treated adults who continued diet had
higher IQs than adults who discontinued diet at
an early age. In addition, adults with PKU who
continued diet performed at a level comparable
to genetic expectations as measured by their
parents’ IQ.8 High Phe levels are known to be
toxic for the fetal brain, as the main conse-
quences of maternal PKU are microcephaly and
mental retardation.9 However, no clear data are
available about the effect of high Phe in the
brain of premature babies and especially about
blood threshold Phe concentrations and/or dura-
tion of high Phe levels on clinical outcome of
these patients. There are only few reports of
preterm infants with PKU in the literature.10-13
Here we report on our experience in the man-
agement of a very preterm infant with classical
PKU.
Case Report
The boy is the first child of non-consan-
guineous parents of Swiss origin. In the 26th
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week of gestation the mother was diagnosed to
have severe arterial hypertension and vaginal
bleedings. In the 27th week premature uterine
contractions were noticed. The mother
received a tocolysis, but due to a placental
abruption the patient was born at 27 weeks of
gestation after antenatal pulmonary matura-
tion with corticosteroids (2¥12 mg of
betamethasone intramuscularly with an inter-
val of 24 h). His growth parameters were
appropriate with a birth weight of 1000 g (10th
percentile), a length of 38 cm (50-90th per-
centile) and a head circumference of 26 cm
(50-90th percentile). Neonatal adaptation was
good for his gestational age. Due to a wet-lung
syndrome he needed respiratory support with
continuous positive airway pressure (CPAP)
for a few days. He was diagnosed with classical
PKU (genotype c.1066-11G>A/c.1315+1G>A)
due to highly elevated phenylalanine (Phe)
level at newborn screening (2800 μmol/L), per-
formed on day 4. On day 7, when newborn
screening results were available, plasma Phe
level was 3696 μmol/L. At this time the boy
received little amounts of enteral nutrition
(Beba Alprem 16%, 60 ml/kg in 12 feeds) com-
pleted with a parenteral nutrition
(Vaminolact®, glucose and lipids) leading to a
protein intake of 3.9 g/kg/day (Figure 1 and
Table 1). The rather high protein intake for
weight and age probably explains the very high
plasma Phe level in this patient. Due to the
diagnosis of PKU Phe intake was arrested for 5
days (Figure 2 and Table 1). During this time
the boy received intravenous glucose and
lipids as well as – due to the lack of a Phe-free
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Table 1. Nutritional intake during the first 35 days of life: Detailed information about total calorie intake (kcal/kg/d), parenteral calorie intake
(kcal/kg/d), enteral calorie intake (kcal/kg/d), total protein intake (g/kg/d), parenteral protein intake (g/kg/d), enteral protein intake, body weight
(kg), phenylalanine (Phe) intake (mg/d and mg/kg/d) and Phe and tyrosine (Tyr) concentrations in plasma (mol/L).
Day Body Phe Tyr Phe Phe Total protein Enteral protein Parenteral Total calorie Parenteral Enteral
weight Plasma Plasma intake intake intake intake  protein intake intake calorie calorie 
(kg) (μmol/L) (μmol/L) (mg/d) (mg/kg/d) (g/kg/d) (g/kg/d) (g/kg/d) (kcal/kg/d) intake intake
(kcal/kg/d) (kcal/kg/d)
1 1 - - 77 77 1 0 1 34 34 0
2 0.87 - - 136 156 1.8 0.1 1.7 49 44 5
3 0.87 - - 241 277 3.3 0.3 3 68 58 10
4 0.871 - - 247 284 3.4 0.4 3 81 67 14
5 0.834 2840 - 252 302 3.6 0.6 3 78 59 19
6 0.872 - - 259 297 3.8 0.8 3 93 66 27
7 0.915 3696 21 279 305 3.9 0.9 3 113 70 43
8 0.9 3403 67 0 0 0.9 0.9 0 90 45 45
9 0.9 2924 93 0 0 1.1 1.1 0 109 57 52
10 0.918 2993 132 0 0 1.3 1.3 0 110 49 61
11 0.9 2231 88 0 0 1.4 1.4 0 111 39 72
12 0.904 - - 0 0 2.2 2.2 0 120 39 81
13 0.944 1467 123 11 12 3.4 2.4 1 121 31 90
14 0.97 - - 3 3 3.1 2.8 0.3 125 22 103
15 0.98 830 48 3 3 3.4 3.1 0.3 136 22 114
16 0.967 - - 0 0 3.3 3.3 0 120 0 120
17 0.986 - - 0 0 3.3 3.3 0 120 0 120
18 1.009 34 58 32 32 3.4 3.4 0 123 0 123
19 1 - - 32 32 3.4 3.4 0 123 0 123
20 1.025 17 52 32 31 3.4 3.4 0 123 0 123
21 1.025 - - 102 100 3.9 3.9 0 137 0 137
22 1.03 - - 102 99 3.9 3.9 0 137 0 137
23 1.05 - - 102 97 3.9 3.9 0 137 0 137
24 1.11 - - 102 92 3.9 3.9 0 137 0 137
25 1.13 16 19 171 151 4.1 4.1 0 142 0 142
26 1.145 - - 171 149 4.1 4.1 0 142 0 142
27 1.185 - - 171 144 4.1 4.1 0 142 0 142
28 1.147 251 26 120 105 3.8 3.8 0 134 0 134
29 1.283 - - 120 94 3.3 3.3 0 117 0 117
30 1.335 - - 120 90 3.3 3.3 0 117 0 117
31 1.34 - - 120 90 3.3 3.3 0 117 0 117
32 1.32 - - 120 91 3.3 3.3 0 117 0 117
33 1.39 127 214 120 86 3.5 3.5 0 125 0 125
34 1.39 - - 120 86 3.5 3.5 0 125 0 125
35 1.4 - - 120 86 3.5 3.5 0 125 0 125
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intravenous amino acid solution - little
amounts of Phe-free formula (65-92 mL/kg/day
with a concentration of 14%, in 2-hourly feeds)
through a nasogastric tube. However, because
enteral feeding was poorly tolerated, the vol-
ume could not be increased rapidly. This led to
poor weight gain and an only very slowly
declining Phe level despite Phe deprivation
(Table 1). In order to promote anabolism and
thus induce protein synthesis and growth, a
parenteral nutrition solution rich in branched-
chain amino-acids, relatively poor in Phe and
unfortunately lacking tyrosine, commonly used
for hepatic insufficiency, was administered
(Aminosteril® Hepa 8%). Under this regimen
(Table 1), Phe plasma levels progressively
diminished and finally normalized on day 18
when intake of natural protein (infant formu-
la) was started. From day 19 to day 25 an oral
supplementation with leucine (4¥25 mg) and
isoleucine (4¥50 mg) was necessary to pre-
vent depletion of these essential amino acids.
The newborn lost a maximum of 16% of his
birth weight, which was attained again on day
18. Parenteral nutrition was stopped on day 16
when the baby tolerated complete enteral
nutrition (only Phe-free formula at a concen-
tration of 15%). During several weeks we tried
to find the balance between the high caloric
and protein requirements, the limited toler-
ance of liquid administration, and the risk of
necrotizing enterocolitis under concentrated
enteral nutrition, all typical problems of pre-
mature children. 
The patient always showed appropriate
growth with height initially on the 10th per-
centile, going up to the 50th percentile at term
and finally reaching the 25th percentile at at 40
months. Weight was initially on the 50th per-
centile going up to the 97th percentile at a cor-
rected age of 3 to 6 months and finally stabiliz-
ing on the 50th percentile. Head circumference
was initially on the 90th percentile and slowly
came up to the 50th percentile by the corrected
age of 18 months stabilizing there. He was
seen for neurodevelopmental follow-up at the
corrected ages of 6 months, 18 months, 24
months and at the chronological age of 40
months. Testing during the first 2 years was
done with the Bayley Scales of Infant
Development and with the French version of
the WPPSI-III (Wechsler Preschool and
Primary Scale of Intelligence, third edition) at
the age of 40 months. Standard neurological
examination has remained normal. Formal
developmental testing has shown scores in the
normal range, with some behavioral issues in
the last examination. He has a rather low Phe
tolerance (~200 mg/d) but keeps a good meta-
bolic control (average plasma Phe level 277
μmol/L during the first two years) on diet.
Discussion
The little reported experience shows that
the management of classical PKU in preterm
infants is not yet established. Adequate treat-
ment of these patients is complicated by two
problems: the lack of a Phe free amino acid
solution for parenteral infusion, and the lack of
reference values for safe Phe plasma concen-
trations related to gestational age. 
Cole et al. published the case of a premature
girl (second twin, less than 32 weeks of gesta-
tion) with a birth weight of 1480 g (Table 2).
She was diagnosed with PKU on day 12 with an
initial very high Phe level of 5670 μmol/L while
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Figure 2. Correlation between phenylalanine plasma levels and phenylalanine intake
during the first 35 days of life: Phenylalanine intake (mg/d) is given in light blue, total
protein intake (g/kg/d) in dark blue, calorie intake in green and plasma phenylalanine
levels in red triangles.
Figure 1. Evolution of parenteral and enteral nutrition during the first 35 days of life: the
body weight (kg) is indicated by the blue curve, total calorie intake (kcal/kg/d) by the
red curve. Proportions of parenteral (dark green) and oral (light green) nutrition are
demonstrated. Start and duration of specific products is marked above the graphic.
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on parenteral nutrition for prematurity. At a
few months of age she had a relatively high
Phe tolerance of 97-128 mg/kg/d. Follow-up was
reported until the age of 16 months with nor-
mal mental and motor development. The
authors draw attention to the fact that Phe-
free amino acid infusions might be necessary
for preterm infants who require long-term
treatment.10 In 1985, Shortland et al. reported
on a girl born at 32 weeks of gestation with a
birth weight of 1560 g (Table 3). On day 13 she
had a plasma Phe level of 1879 μmol/L. She
had a Phe tolerance of less than 90 mg/kg/d
and needed between 270 and 290 mg/kg/d of
Tyr to achieve a normal weight gain. The
authors concluded that the intake of Tyr
seemed to be a growth limiting factor.13
Randall et al. described a boy born at 30 weeks
of gestation with a birth weight of 2360 g and
an initial Phe level of 1926 μmol/L on day 19
(Table 3). After cessation of natural protein
intake Phe plasma levels normalized rapidly,
but upon reintroduction of Phe he needed a
Phe intake as high as 100 mg/kg/d to maintain
plasma Phe levels in the low normal range.
Elevated Phe requirements normalized at
term. The authors concluded that preterm
infants with classical PKU may require higher
phenylalanine intakes in order to meet
demands of growth.12 Hennermann et al.
described a premature girl (27 weeks of gesta-
tion, birth weight 1080 g) known to be het-
erozygous for classical PKU due to prenatal
diagnosis in a context of a positive family his-
tory (Table 3). On day 6 while on parenteral
nutrition with a Phe intake of 160 mg/kg/d, she
had a slightly elevated serum Phe level of 400
μmol/L that further rose to 515 μmol/L on day
8. A Phe-restricted parenteral and enteral
nutrition was necessary to maintain normal
serum Phe levels until the 42nd day of life. At
term serum Phe levels had normalized. The
authors hypothesize that heterozygosity for
PKU might be a risk factor for transient hyper-
phenylalaninemia in preterm infants and
could be explained by the combination of
immature liver function and the genetically
determined reduced PAH activity.11
Our patient is the most premature reported
PKU patient so far, with the longest reported
neurodevelopmental follow-up. Despite a long
period (17 days) of highly elevated Phe levels
in the postnatal period he shows normal psy-
chomotor development without neurological
impairment. Given the known toxicity of high
Phe blood levels on the developing brain14-16
and the irreversible brain damage that it can
cause in newborns when exposed to it even for
short periods of time,2 the outcome of our
patient suggests that the premature brain may
still have enough plasticity to overcome the
insult of at least 2 weeks of extremely high Phe
concentrations. Furthermore, it is possible
that brain damage has been limited by prompt
availability of sufficient Tyr and other large
neutral amino-acids through the parenteral
amino-acid solution, and the early supplemen-
tation of long-chain polyunsaturated fatty
acids (LCP) which are supposed to be involved
in neural and cognitive development of
preterm infants.17
Our patient remained free of the frequent
complications of enteral feeding in premature-
ly born infants. The occurrence of one of these
complications would have made management
much more difficult. 
Conclusions
Even if the concurrence of significant pre-
maturity (in CH 1:100 for <32 weeks of gesta-
tion) and PKU (in CH 1:8000) is rare
(1:800,000), there is a clear need for appropri-
ate Phe-free parenteral nutrition in order to
guarantee optimal treatment in PKU patients
with gastro-intestinal complications of prema-
turity. In the absence of a specific Phe-free
parenteral nutrition, amino acid solutions
used for hepatic disorders are more appropri-
ate than classical amino acid solutions for pre-
maturity, because of their high content of
essential amino acids and relatively low
amount of aromatic amino acids. At present,
dietary treatment of premature infants with
PKU depends on the baby’s tolerance of enter-
al nutrition. 
This case points out the importance of a
timely diagnosis of PKU in premature babies,
as these patients are likely to receive high
amounts of parenteral proteins during the first
weeks of life. Due to efficient logistics of new-
born screening in our country, the turnaround
time of results is limited to 2-3 days; therefore
diagnosis is usually made within the first week
of life. This may not be the case in other coun-
tries where preterm PKU babies may be
exposed for longer time to extremely high Phe
levels. 
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